Table 1.

Antidiabetics and COVID-19 adapted from singh et al. [26].

Anti-diabetic drug	Potential benefit	Final results
Metformin	It has been described as a potent drug to reduce mortality with its use in patients with type 2 diabetes and covid-19 infection.	Its use should be continued in patients with type 2 diabetes mellitus until hospitalized or unless contraindicated. It is unclear at this point whether its potential mortality benefit extends to inpatient use or in non-diabetic covid-19 patients.
Pioglitazone	Possible reduction in inflammatory markers.	There is no significant evidence to promote its use in patients with diabetes mellitus and covid-19 infection. Further studies are needed to elucidate its potential benefit.
Sulfonylureas	Potential reduction in disease severity.	Studies have not demonstrated a significant difference in the rate of ICU admissions or disease severity with its use.
DPP-4 inhibitors	It has been proposed that DPP-4 could be involved with the receptor-binding domain of SARS-CoV-2. Furthermore, it could offer anti-inflammatory, anti-fibrotic and immunomodulatory effects. Several researchers have proposed its use as a repurposed agent for COVID-19.	Several studies found no significant difference in rate mortality rate, poor prognosis, or rate of ICU admission. However, others did find some benefit in the rate of intubation, the severity of disease, and discharge rate. Further studies are needed to elucidate its potential benefit.
SLGT-2 inhibitors	Anti-inflammatory properties; decrease in lactic acidosis of dapagliflozin, which could potentially reverse acid-base balance in hypoxia.	Studies have not demonstrated a significant difference in disease severity or mortality rates.
GLP-1 receptor agonists	Improvement in right ventricular function and anti-inflammatory effects during acute lung injury.	There is limited data available. Some studies have shown no significant difference in the rate of ICU admissions or mortality.